Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) with GLP-1, GIP and Glucagon (Triple-G) Receptor…
STAMFORD, Conn., June 05, 2026 (GLOBE NEWSWIRE) -- Oban BioPharma today announced that preclinical data for OBT-676, a lead small-molecule candidate for the treatment of obesity and type 2 diabetes, has been selected for a late-breaking presentation at the upcoming American Diabetes Association (ADA) 86th Scientific Sessions being held from June 5th-8th in New Orleans, LA. The study characterizes OBT-676 as a new molecular entity that achieves potent full agonism at the amylin and calcitonin receptors (DACRA) while simultaneously delivering partial agonism across the GLP-1, GIP, and glucagon (Triple-G) pathways. OBT-676 demonstrated significant reduction in food intake and adipose-selective weight loss in the industry-standard rat diet-induced obesity (DIO) model.
"The OBT-676 data being presented at ADA underscores a significant leap in the evolution of small molecule, multimodal metabolic therapies”, said Derek Chalmers, Ph.D., D.Sc., Co-Founder & CEO of Oban BioPharma. “With OBT-676, and a series of related analogs, we have moved beyond incretin receptor-focused injectable peptides to an oral small molecule class targeting multiple metabolic systems, encompassing potent amylin receptor activation paired with balanced incretin and glucagon receptor signaling. These DACRA/Triple-G small molecule compounds have the potential of shifting the treatment goal for millions of patients managing chronic metabolic diseases from simple weight reduction to high-quality metabolic restoration, prioritizing adipose-biased weight loss and superior tolerability with an orally available drug.”
Presentation Details:
Title: OBT-676, a Novel Oral Small Molecule Combining Full DACRA Activity with “Triple-G” Partial Agonism for the Treatment of Metabolic Diseases
Poster #: LB-2848
Session: Late Breaking
Date: Sunday June 8th
Time: 12.30pm-1.30pm CT
Summary: OBT-676 exhibited picomolar potency and full agonism at AMY-1, AMY-3, and calcitonin receptors along with calibrated partial agonism at GLP-1, GIP and Glucagon receptors. Administration of OBT-676 in diet-induced obese rats resulted in significant, dose-dependent reductions in food intake and adipose-selective weight loss.
2848-LP ADA Poster Final 29May26 QR.pdf
About Oban BioPharma
Oban BioPharma is a privately held biotechnology company focused on the development of novel oral small molecule GPCR-targeted therapeutics for metabolic and CNS diseases. Oban combines the power of computational structural and chemotype analysis with AI-based “druggability” filters to create a faster, more efficient path to new medicines.
For additional information please visit: https://obanbiopharma.com
Contact: info@obanbiopharma.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
